Literature DB >> 10211116

Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia.

N J Maitland1, S Conway, N S Wilkinson, J Ramsdale, J R Morris, C M Sanders, J E Burns, P L Stern, M Wells.   

Abstract

Specific antibodies against the C-terminus of E2, produced by affinity purification of polyclonal antisera, have been used to identify the cellular populations which express the HPV 16 E2 transcription factor, in a series of formalin-fixed, paraffin-embedded cervical tissues. Cases were selected for both the presence of HPV 16 DNA (confirmed by multiple gene-specific PCR detections) and the presence of multiple grades of cervical intraepithelial neoplasia (CIN). The data indicate that E2 expression is highest in CIN I and in koilocytic lesions. Lower expression was observed in CIN II and little in CIN III lesions. In contrast, there was some restoration of E2 expression in invasive carcinomas, although the intracellular distribution was much more diffuse. The location of E2 expression to the superficial layers of the cervical epithelium, as well as the occurrence of some basal expression in CIN I, suggests that antibodies against HPV 16 E2 could be a useful adjunct to standard histological techniques for the detection of 'at-risk' patients as part of a cervical screening programme.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10211116     DOI: 10.1002/(SICI)1096-9896(1998110)186:3<275::AID-PATH159>3.0.CO;2-E

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

1.  Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression.

Authors:  Sophie Bellanger; Chye Ling Tan; Yue Zhen Xue; Sébastien Teissier; Françoise Thierry
Journal:  Am J Cancer Res       Date:  2011-01-24       Impact factor: 6.166

2.  The human papillomavirus type 18 E2 protein is a cell cycle-dependent target of the SCFSkp2 ubiquitin ligase.

Authors:  Sophie Bellanger; Chye Ling Tan; Wenlong Nei; Ping Ping He; Françoise Thierry
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

3.  SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells.

Authors:  Maria G McPhillips; Thanaporn Veerapraditsin; Sarah A Cumming; Dimitra Karali; Steven G Milligan; Winifred Boner; Iain M Morgan; Sheila V Graham
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 4.  The papillomavirus E2 proteins.

Authors:  Alison A McBride
Journal:  Virology       Date:  2013-07-10       Impact factor: 3.616

Review 5.  Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies.

Authors:  Sheila V Graham
Journal:  Future Microbiol       Date:  2010-10       Impact factor: 3.165

Review 6.  The role of ubiquitin and ubiquitin-like modification systems in papillomavirus biology.

Authors:  Van G Wilson
Journal:  Viruses       Date:  2014-09-24       Impact factor: 5.048

Review 7.  Mechanisms by which HPV Induces a Replication Competent Environment in Differentiating Keratinocytes.

Authors:  Cary Moody
Journal:  Viruses       Date:  2017-09-19       Impact factor: 5.048

8.  Human papillomavirus type 16 E2 protein transcriptionally activates the promoter of a key cellular splicing factor, SF2/ASF.

Authors:  Sarah Mole; Steven G Milligan; Sheila V Graham
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

9.  RNA splicing factors regulated by HPV16 during cervical tumour progression.

Authors:  Sarah Mole; Melanie McFarlane; Thanaporn Chuen-Im; Steven G Milligan; David Millan; Sheila V Graham
Journal:  J Pathol       Date:  2009-11       Impact factor: 7.996

10.  Life cycle heterogeneity in animal models of human papillomavirus-associated disease.

Authors:  Woei Ling Peh; Kate Middleton; Neil Christensen; Philip Nicholls; Kiyofumi Egawa; Karl Sotlar; Janet Brandsma; Alan Percival; Jon Lewis; Wen Jun Liu; John Doorbar
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.